Physician profile
Robert Bridge
NPI 1700882990
$5,575.93
in general payments reported to CMS, 2019-2025
15 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,689 · 2020: $94.16 · 2021: $838 · 2022: $339 · 2023: $808 · 2024: $483 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,534 · Education: $81.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.18 |
| Education | $81.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,923.91 | 2019-2024 | Audion Et Dilation System |
| Optinose US, INC. | $1,173.46 | 2019-2024 | |
| Genzyme Corporation | $674.87 | 2019-2025 | |
| Acclarent, INC | $390.08 | 2019-2023 | Trudi Nav Cable |
| Intersect Ent, INC. | $367.21 | 2021 | |
| Glaxosmithkline, LLC. | $347.20 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $199.56 | 2021-2025 | Dupixent, Libtayo |
| Aerin Medical INC. | $187.35 | 2023-2025 | |
| Neurent Medical Limited | $90.97 | 2023-2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Sanofi-Aventis U.S. LLC | $81.99 | 2023 | |
| Preceptis Medical, INC. | $54.48 | 2022 | |
| Mimedx Group, INC. | $23.21 | 2025 | |
| Arrinex, INC. | $22.61 | 2019 | |
| Smith+Nephew, INC. | $21.69 | 2024 | Halo |
| Boston Scientific Corporation | $17.34 | 2023 | Upsylon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.